Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Lymphoma, Follicular 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Prostatic Neoplasms 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia 1Hepatic Impairment 1

Interventions

tislelizumab 3Paclitaxel 3Nivolumab 3pembrolizumab 2atezolizumab 2Docetaxel 2ulocuplumab 1tazemetostat 1tazarotene 1seviteronel 1rucaparib 1romiplostim 1phosphorylethanolamine 1pertuzumab 1neratinib 1magrolimab 1fluzoparib 1fludarabine 1epacadostat 1durvalumab 1camrelizumab 1Trastuzumab 1Sunitinib 1Poly(ADP-ribose) Polymerase Inhibitors 1LY2510924 1EC145 1Cyclophosphamide 1CH5183284 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Solid Tumor × tazemetostat × Clear all
NCT05023655 2026-03-17

Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation

Prisma Health-Upstate

Phase 2 Terminated
20 enrolled
Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡